echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Shanghai: 819 drugs will be fully negotiated tomorrow! Involving hundreds of pharmaceutical enterprises such as AZ, Bayer, Shiyao, xinlitai, etc., is it a foregone conclusion to reduce the price in an all-round way?

    Shanghai: 819 drugs will be fully negotiated tomorrow! Involving hundreds of pharmaceutical enterprises such as AZ, Bayer, Shiyao, xinlitai, etc., is it a foregone conclusion to reduce the price in an all-round way?

    • Last Update: 2019-03-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Now it is gradually clear that no matter whether the country negotiates drugs, purchases drugs centrally, evaluates drugs through consistency or any other drugs, when the role of national health insurance as a strategic buyer is increasingly clear, price reduction is an irresistible thing From this point of view, whether it is local enterprises or transnational pharmaceutical enterprises, whether it is imitated varieties or original research products, it may not be able to stay out of business On March 6, Shanghai Sunshine pharmaceutical purchasing network released the work tips of "fully implementing the open price negotiation purchase of drugs on the Internet" It is clear in the document that since March 7, 2019, a total of 819 varieties have been fully negotiated in Shanghai The reference standard for price negotiation is the original bid price of relevant products and the purchase price of 15 provinces and cities This is the third batch of the products that have won the bid in Shanghai In September 2018, Shanghai Municipality issued the notice on the full implementation of public bargaining purchase of drugs on the Internet, which clearly stipulated that except for narcotic drugs priced by the government, class I psychotropic drugs, and drugs designated by the state for production, negotiated by the state and their generic drugs, bid winning products purchased in volume, included in medical insurance payment and self paid drugs with individual quota, the rest were All varieties included in the 2017 Shanghai Medical Insurance catalogue shall be purchased through open price negotiation on the Internet Coincidentally, on March 4, Guangxi Zhuang Autonomous Region also announced the latest price reference for a number of generic drugs with the same quality and efficacy as the original drugs According to the regulations, the generic drugs that pass the consistency evaluation can be directly purchased on the Internet in Guangxi However, enterprises need to independently fill in the shortlist price of relevant varieties in the lowest five provinces in the country, and take this as the reference standard for price negotiation That is to say, even if the varieties are evaluated through consistency, the price that should be negotiated should be reduced According to the reference price published this time, the decline of some enterprises is not small Take the entecavir dispersible tablet of Anhui Baker biology as an example, the enterprise price is 126 yuan, but the average price of the five provinces is 79.89, with a difference of 37% It can be said that now it is gradually clear that no matter whether the country negotiates drugs, purchases drugs centrally, evaluates drugs through consistency or any other kind of drugs, when the role of national health insurance as a strategic buyer is increasingly clear, price reduction has become an unstoppable thing From this point of view, whether it is local enterprises or transnational pharmaceutical enterprises, whether it is imitated varieties or original research products, it may not be able to stay out of business 1 Enterprises: both domestic and international enterprises are busy with price adjustment For enterprises, price reduction, on the one hand, conforms to the top-level trend, on the other hand, is an urgent need to compete for market share In the results of the 4 + 7 city drug centralized purchase, AstraZeneca's gefitinib tablets won the bid at a price of 547 yuan per box (250mg * 10 tablets), with a decrease of over 76% Qilu pharmaceutical, which lost the election, quickly launched a bid Since the end of last year, it has gradually applied to adjust the bidding price of gefitinib nationwide and launched a price reduction strategy At present, Qilu's gefitinib has applied for price reduction in Shaanxi, Heilongjiang, Zhejiang, Jilin and other places The packaging price of the same specification with AstraZeneca has been reduced to 498 yuan per box, 8.9% lower than AstraZeneca's bid price In addition, from the recent trend of applying for price reduction products, lenalidomide and leuprorelin acetate sustained-release microspheres for injection have a high frequency of occurrence Both drugs are not in the 4 + 7 purchase list, but they are actively bidding for price reduction in many places The price of lenadelamine capsule of Shuanglu pharmaceutical has been adjusted in Hunan, Inner Mongolia, Shandong and other places Taking 10mg as an example, the price before adjustment is 19676 yuan per bottle (28 capsules), 5350 yuan after adjustment, with a drop of 72.8% Lizhu pharmaceutical's sustained-release microspheres of leuprorelin acetate for injection applied for price adjustment in Sichuan, and the adjusted bid price was 1295.9 yuan The price of leuprorelin acetate sustained-release microspheres for injection of Beijing Bonte was also adjusted from 1303 yuan per box to 1291.95 yuan in Hunan, Anhui and other places Although irbesartan tablets and risperidone tablets of Huahai pharmaceutical industry have successfully won the bid in the national 4 + 7 drug collection, Huahai has carried out linkage price reduction outside the pilot area For example, on March 4, Zhejiang Pharmaceutical and machinery purchasing center issued a notice that it had agreed to lower the prices of irbesartan and risperidone tablets approved by Huahai The price reduction of pemetrexed disodium for injection is also spreading According to the results of national 4 + 7 drug centralized purchase, Sichuan Huiyu pharmaceutical's injection products were selected successfully, and the price of 500mg was 2776.97 yuan per box The price of pemetrexed disodium for injection of the same specification of Yangzi River has also been adjusted in Inner Mongolia, from 4300 yuan to 3365 yuan, which is higher than the bid price of Huiyu, but the decrease is also as high as 20% In addition, pemetrexed disodium for injection from Qilu and Lilly also applied for price adjustment in different places In February, the price limit of capecitabine tablets of Roche pharmaceutical in Shaanxi was also adjusted from 368.69 yuan per box (0.5g * 12 tablets) to 348.4 yuan, and the product did not appear in the 4 + 7 selected varieties Price reduction, no doubt, has become a strong wind of national drug collection On the whole, local enterprises adopt the strategy of low price to recover the market For multinational pharmaceutical enterprises, experts predict that Lilly, Geely and other enterprises are authorized in the target city by foreign countries In the future, under the effect of 4 + 7 and its landing policy, such a strategy may also be displayed 2 Bidding and purchase: different ways to encourage price adjustment and provinces and cities to launch policies in promoting drug price reduction in succession, but forcing enterprises to take the initiative in price reduction Under the condition that the state vigorously promotes the price reduction of anti-cancer drugs, the trend of applying for price reduction of anti-cancer drugs is obvious; in addition, with the publication of the government work report in 2019, it is pointed out that the proportion of reimbursement for serious disease insurance should be increased from 50% to 60%, and the common chronic diseases should be well prevented In the future, the treatment products in these fields should also become the key areas of price reduction in the centralized purchase of national drugs Many provinces and cities are pushing forward drug price reduction in different ways On February 26, Liaoning Provincial bidding and purchase department issued a notice on carrying out the gradient price reduction of 4 + 7 urban drugs purchased in a centralized way and not selected drugs The price reduction methods are mainly divided into three categories: first, the drugs that have completed the gradient price reduction in Shanghai will implement the price reduction results in Shanghai; second, for other drugs that have not been included in the gradient price reduction range in Shanghai, the current online purchase price is required On the basis of this, the online purchase can be continued only after the gradient price reduction is realized according to the price difference (based on the bottom price of the middle selection price), and the price reduction range shall be further increased if the price difference is large For the original research drugs, reference preparations and generic drugs that have passed the consistency evaluation of national quality and efficacy, the drug manufacturers shall, within the prescribed time limit, independently declare the price reduction at a price no higher than that of the drugs that have completed the gradient price reduction in Shanghai The purchase price of other generic drugs shall be lower than the price selected from the same variety before continuing online purchase The drug manufacturer shall, within the prescribed time limit, apply for price reduction independently at a price lower than the selected price of the same variety In February, Sichuan provincial centralized procurement service center of pharmaceutical machinery issued the notice on the implementation of the dynamic adjustment results of the first batch of online anti-cancer drugs in 2019, which adjusted the price of 67 drugs applying for dynamic price limit adjustment Inner Mongolia pharmaceutical equipment centralized purchase service center also issued the eighth batch of notice to reduce the purchase price of some drugs, and Yangzijiang, Qilu and Hengrui became the main enterprises participating in the price adjustment In addition, Shanxi Provincial Drug Purchase Center issued the notice on publicizing the dynamic linkage price information of drug purchase of public medical institutions in the whole province, which involves the price reduction of 8 commonly used drugs that are not seriously ill Recently, Guangxi also announced that the fourth batch of generic drugs with the same quality and efficacy as the original research drugs were included in the price reference price of the direct online purchase part of the varieties, in which the reference price is based on the lowest 5 provincial shortlisted prices independently filled in and confirmed by relevant enterprises The trend of bidding and purchase in these places has released that price reduction is the general trend, especially for the varieties and enterprises that have not won the bid, they need to lay out the price strategy in bidding and purchase, which is also a strategy to resist the market impact of 4 + 7 3 Medical insurance: strengthen the identity of strategic purchasers In fact, from a series of actions of the medical insurance bureau during the national two sessions, the centralized purchase of drugs at the national level is bound to spread across the country The identity of national health insurance as a strategic buyer will be further strengthened in the future Previously, on March 5, the state health insurance bureau issued the opinions on supporting measures for centralized purchase and use of "4 + 7" drugs, and clarified the payment standards for related drugs At the same time, on the same day, the medical insurance bureau also held a symposium on the construction of national drug consumables bidding and purchasing platform, which plans to promote the construction of national unified drug procurement, distribution and settlement integration platform, unify drug data standards, and build an efficient regulatory purchasing platform As for the payment standard, the guidance document of 4 + 7 drug centralized purchase of the medical insurance bureau points out that for the original research drug, reference drug and generic drug under the same generic name, in principle, the middle price of centralized purchase is the payment standard of the generic drug, and the medical insurance fund is settled according to the same payment standard The most concerned content of this document is to clarify the payment standard of unselected drugs, which has been the most confusing to the industry before, and its purpose is also very clear, "encourage non unselected enterprises to take the initiative to reduce prices and converge to the payment standard" It is pointed out in the document that if the price of non selected drugs is more than twice the price of selected drugs at the end of 2018, the payment standard is to reduce the original price by no less than 30% in 2019, and to adjust the price of selected drugs as the payment standard in 2020 or 2021 Standard: if the price of non selected drugs at the end of 2018 is within 2 times of the selected price and the selected price (including 2 times), the selected price shall be the payment standard in principle; if the price is lower than the selected price, the actual price shall be the payment standard For generic drugs that fail to pass the consistency evaluation under the same generic name, no transition period will be set, and the payment standard in 2019 will not be higher than the price of selected drugs In fact, before the document was issued, it was shocked by the centralized purchase of 4 + 7 drugs No matter the selected or not, they have played their own cards in the price strategy following the general trend since 2019.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.